Medication compare
Compounded vs Brand-Name GLP-1: a head-to-head comparison of efficacy, dosing, pricing, FDA status, and which is right for you.
Brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) are FDA-approved finished drugs manufactured by Novo Nordisk and Eli Lilly. Compounded GLP-1s are prepared by licensed compounding pharmacies (503A or 503B) on a per-patient basis. Compounded versions are not FDA-approved as finished drugs.
| Dimension | Brand-name | Compounded |
|---|---|---|
| FDA approval status | FDA-approved | Not FDA-approved |
| Manufacturer | Novo Nordisk / Eli Lilly | Licensed compounding pharmacies |
| Price (cash, monthly) | $968–$1,349 | $199–$499 |
| Insurance coverage | Possible with prior auth | Not covered |
| Format | Prefilled pen | Multi-dose vial + syringe |
| Regulatory framework | FDA NDA approval | State pharmacy boards + USP standards + FDA 503A/503B oversight |
FDA issued updated guidance in April 2026 tightening advertising and prescribing standards for compounded GLP-1 products, particularly around efficacy claims, label parity, and pharmacy verification. Reputable telehealth providers like NexLife operate within this framework with LegitScript-certified pharmacy partners.
Compounded medications prepared by licensed, accredited pharmacies under physician supervision are generally considered safe by the patient-care framework. Risks rise sharply when pharmacies are unverified, ingredients are not third-party tested, or providers do not provide clinical oversight. Verify LegitScript certification, ask about pharmacy accreditation (PCAB), and confirm physician-led prescribing.
If your insurance covers Wegovy or Zepbound and you can complete prior authorization, brand-name is straightforward. If insurance denies (very common for weight-loss-only) or you don't have insurance, compounded is typically 4–7× cheaper than brand list price. Always work with a physician-led, LegitScript-certified provider.